Dr. Lau received her Ph.D. from the University of Sydney, Australia, where her research focused on the development of novel diagnostic platforms for the diagnosis of invasive fungal diseases. She completed her CPEP Clinical Microbiology Fellowship training at the NIH Clinical Center and is board-certified through the American Board of Medical Microbiology. In 2013, she joined the Clinical Microbiology Service in the Department of Laboratory Medicine of the NIH Clinical Center, where she co-directed the Bacteriology, Specimen Processing, Parasitology, and Molecular Epidemiology sections. In 2018, Dr. Lau was promoted to Chief of the Sterility Testing Service in DLM to support the NIH-wide cGMP aseptic processing and manufacturing of cellular therapy and drug pharmaceuticals for NIH clinical protocols.
Dr. Lau's translational research focus on the development of new rapid diagnostic platforms for microbial identification and the detection of resistance mechanisms using molecular-based techniques and mass spectrometry. In 2014, Dr. Lau was recognized with the prestigious Forbes 30 Under 30 award in Science and Healthcare for her development of the NIH Mold MALDI-TOF MS Database.
More recently, Dr. Lau has branched into the field of current good manufacturing practice (cGMP) product sterility testing, where she leads a team of 11 to support the NIH intramural cGMP program for cell-, gene-, and immunotherapy, as well as drug development. In this role, Dr. Lau applies her research interests of rapid diagnostics to evaluate system performances within the cGMP setting. Her expertise in this unique area of regulatory microbiology is readily sought in the clinical microbiology field, where requests for sterility testing of biopharmaceutical products is becoming more widespread as cellular therapies become the norm for the treatment of a variety of acquired and/or genetic diseases.